No Data
Heshi Ophthalmology (301103.SZ): Currently, the total revenue of hospitals outside the province has increased year-on-year, but it has not yet passed the incubation period.
On November 20th, Gelonghui reported that He’s Ophthalmology (301103.SZ) recently expressed during investor relations activities that the total revenue of hospitals outside the province has seen a year-on-year increase, but has not yet passed the cultivation period. Once the number of patient visits reaches a certain scale, the profit contribution of hospitals outside the province will also see a significant increase.
He Family Eye Hospital (301103.SZ): The company's optical business accounts for one third of the revenue.
Gelonghui November 20th | Heshi Ophthalmology (301103.SZ) stated in recent investor relations activities that the company's optometry business accounts for one-third of the revenue, with core products being corneal reshaping lenses and defocus lenses. Due to the soft consumer market and the lagging non-essential consumer demand, prices have fallen year-on-year.
Express News | Hani Ophthalmology: Advance Manufacturing Fund shareholder plans to reduce shareholding by no more than 2% of the company's shares
Haixi Ophthalmology (301103.SZ): Not ruled out business expansion through mergers and acquisitions.
Gelonghui November 13th | Heshi Ophthalmology (301103.SZ) stated at an investor relations event that the company adheres to a global strategy of medical consumption, focusing on the development of optometry clinics and optometry centers, and will later carry out a combination of self-built and franchised chains, focusing on the jing-jin-ji, chengyu urban agglomeration, cni zhujiang index, and cni yangtze index areas and other economically developed regions for pilot trials. At the same time, the company does not rule out business expansion through means such as mergers and acquisitions.
Express News | Moutai's fund is once again making a move, planning to increase its investment in the healthcare industry by 0.554 billion yuan.
Ho\'s Ophthalmology: Report for the third quarter of 2024
No Data
No Data